تجربة إيس رينو™ رينو السريرية

تجربة إيس رينو™ رينو السريرية

  • Title: ACE Reno™, Pico Cell Matrix and Its Effect on eGFR & Renal Function
  • Clinical Trial ID: NCT07187713
  • Product: ACE Reno
    (oral/transmucosal solution containing standardised bio-active peptides via Pico Cell Matrix)
READ MORE

Background

Chronic kidney disease (CKD) and declining estimated glomerular filtration rate (eGFR) represent significant global health burdens. Our proprietary Pico Cell Matrix technology processes tissue-derived peptides into nanometer and picometer-scale fragments to deliver regenerative potential. ACE Reno™ applies this technology specifically for renal function support.

Study Purpose

The purpose of this trial is to evaluate both the safety و efficacy of ACE Reno when administered via the oral-transmucosal route in adult participants with reduced eGFR (kidney function impairment). 

Key Features of the Trial

  • Intervention: ACE Reno, oral/transmucosal solution, containing Pico Cell Matrix-derived peptides.
  • Primary Outcome: Change in eGFR over time (e.g., improvement or stabilisation of kidney filtration function).
  • Design: Single arm (or as specified in the registry) evaluating safety and renal function outcomes in enrolled participants.
  • Enrollment: Adult subjects with impaired renal function (reduced eGFR) meeting inclusion/exclusion criteria specified in the registry.
  • Duration & Follow-Up: As specified in the ClinicalTrials.gov record (visit schedule, assessment intervals), to monitor both renal markers and adverse events.

Why This Trial Matters

  • It represents the first clinical investigation of ACE Reno in humans targeting renal function using the Pico Cell Matrix technology.
  • If successful, ACE Reno may offer a novel, non-invasive option for kidney support and regeneration, particularly relevant for patients with CKD or declining eGFR.
  • Conducting this trial underscores our commitment to rigorous clinical evaluation and transparency as we advance our product pipeline toward evidence-based outcomes.

Disclosure & Notes

  • This study is conducted in accordance with Good Clinical Practice (GCP) standards.
  • The product ACE Reno is currently investigational in this clinical trial; results are not yet conclusive, and the product is not approved for the treatment of kidney disease.
  • Participants should be informed of the potential risks and benefits as outlined in the trial informed consent form.
  • The trial status (e.g., recruiting, active, completed) can be checked on ClinicalTrials.gov for any updates.